Explore the latest evidence-based insights on probiotics, synbiotics, and microbiome-targeted therapies across critical care, oncology, surgery, aging, metabolic health, and infectious diseases. This curated collection highlights systematic reviews, randomized trials, mechanistic studies, and translational research shaping the future of precision microbiome interventions and preventive medicine in 2026.
Intensive care unit–acquired infections contribute significantly to morbidity and mortality in critically ill adults, with inconsistent evidence for probiotic prevention. This scoping review of ten studies (>6,500 patients) shows that probiotic efficacy is strongly dependent on strain selection, treatment duration, and dosage. Multi-strain formulations containing Lactobacillus acidophilus LA-5, administered for at least 14 days at doses ≥ 5 × 10⁹ CFU/day, were consistently associated with reductions in ICU-acquired infections, whereas shorter durations, lower doses, or single-strain regimens showed no benefit. Overall, probiotics may reduce ICU-acquired infections under specific conditions, but heterogeneity and limited evidence prevent firm clinical recommendations, underscoring the need for large, strain-specific randomized trials.
Read MoreEvidence synthesized from multiple meta-analyses indicates that probiotic and synbiotic supplementation can meaningfully shorten hospital stay in patients undergoing surgery. Analysis of 48 clinical trials involving 6,378 participants showed that probiotics reduced hospital length of stay by approximately one day compared with placebo, while synbiotics achieved a larger reduction of about 2.6 days, both supported by moderate-certainty evidence. In contrast, synbiotic supplementation did not significantly affect ICU stay duration, and neither probiotics nor synbiotics were associated with a significant change in postoperative mortality risk. Overall, the findings support the role of probiotic and synbiotic interventions in improving postoperative recovery by reducing hospitalization duration, while highlighting limited evidence for benefits on critical care outcomes or survival.
Read MoreThe human gut microbiome plays a central role in health, but the effectiveness of conventional probiotic therapies is often limited by variability in host–microbe–environment interactions. Differences in biological and environmental factors contribute to inconsistent probiotic responses across individuals. Integrating cross-sectional and longitudinal multi-omics data provides a framework to better predict probiotic treatment outcomes and host metabolic responses. Recent methodological advances in probiotic strain mining and engineering enable the rational design of functionally enhanced, personalized probiotics. Collectively, these developments highlight the potential of data-driven models and precision-engineered microbial therapeutics to overcome current limitations and support future microbiome-informed nutrition and personalized interventions.
Read MoreCrohn’s disease is associated with intestinal dysbiosis, leading to interest in microbiome-targeted therapies such as probiotics, prebiotics, synbiotics, and fecal microbiota transplantation. Evidence from five studies shows that probiotics and synbiotics reduce disease activity scores, improve mucosal integrity, and modulate inflammatory cytokines, while prebiotics increase Bifidobacterium without achieving clinical remission. Fecal microbiota transplantation did not significantly improve clinical or endoscopic remission, although inflammatory markers decreased within treatment groups. Overall, these therapies show biological and anti-inflammatory effects, but evidence remains insufficient for routine clinical use, supporting their consideration mainly as adjuncts to standard treatment.
Read MoreEvidence from ten randomized controlled trials involving 732 patients suggests that probiotic and synbiotic supplementation can improve lumbar spine bone mineral density and reduce parathyroid hormone levels in individuals with osteoporosis. No increase in adverse events was observed, indicating a favorable safety profile. However, supplementation showed no significant effects on hip bone mineral density or most bone turnover markers. Overall, probiotics and synbiotics appear to be safe adjunctive options for osteoporosis management, but larger and well-designed trials are required to confirm their clinical benefit.
Read MoreIn an era dominated by antibacterial strategies, the therapeutic potential of beneficial bacteria has gained increasing recognition. Live microorganisms naturally present in yogurt and other fermented foods can positively influence the human microbial ecosystem, both internally and externally. These organisms are collectively referred to as probiotics, a term derived from Greek meaning “for life.”The use of probiotic products has expanded substantially, with individuals adopting them to manage specific health conditions or to support general well-being. Market analyses indicate a rapid rise in global demand; a 2017 industry report estimated worldwide probiotic supplement sales at approximately USD 3.7 billion in 2016, with projections reaching nearly USD 17.4 billion by 2027.
Read MoreA landmark UK clinical trial has demonstrated for the first time that targeted modulation of gut microbiota using plant-based nutrition combined with a probiotic supplement can slow prostate cancer progression while improving overall health. In 212 men with prostate cancer under active surveillance and rising PSA levels, participants receiving the probiotic alongside a standardized plant-derived supplement showed a 44% reduction in PSA progression, supported by MRI evidence of reduced disease progression. Additional benefits included improved urinary symptoms, better erectile function, reduced systemic inflammation, and enhanced physical strength, providing the first robust human evidence that gut-directed nutritional interventions can positively influence prostate cancer outcomes and quality of life.
Read MoreThe development of probiotic strains is a growing focus in research and industry, yet laboratory-proven functionality often fails to translate into industrial stability and scalability, limiting commercialization. This review examines the probiotic development pipeline, highlighting strain selection, resilience-enhancing strategies, and regulatory frameworks, with emphasis on stressors such as heat, oxygen, and digestion that reduce viability. Although adaptive approaches report survival gains of up to 31-fold after heat shock and nearly 100-fold through microencapsulation, outcomes remain highly strain-specific and poorly reproducible. Comparative analysis of regulatory systems in the United States, European Union, Japan, Korea, and China further reveals significant heterogeneity that complicates global market entry. Overall, the findings underscore the need for harmonized evaluation frameworks and coordinated academia industry regulatory collaboration to support effective, safe, and scalable next-generation probiotics.
Read MoreRecent evidence suggests that aging-related physiological changes are strongly influenced by shifts in gut microbiota rather than by chronological age alone. Reduced microbial diversity and loss of short-chain fatty acid–producing taxa during aging impair intestinal barrier function and promote chronic low-grade inflammation, affecting immune, metabolic, and mitochondrial pathways. In contrast, microbiota enriched with butyrate- and polyamine-producing species support epithelial integrity, metabolic flexibility, and immune balance, while gut–organ axes modulate tissue-specific aging. Dietary interventions, probiotics, and emerging postbiotic strategies show potential to partially restore age-associated microbial functions, although responses remain highly individual.
Read MorePancreatic ductal adenocarcinoma (PDAC) remains a major therapeutic challenge despite advances in cancer treatment due to its insidious onset, late-stage diagnosis, and marked resistance to therapy, resulting in one of the lowest five-year survival rates among malignancies. Consequently, preventive strategies that reduce pancreatic cancer risk are of high clinical relevance. Recent work by Parida et al., published in Cellular and Molecular Gastroenterology and Hepatology, adopts an integrative, multi-organ systems approach to pancreatic cancer prevention by targeting the gut microbiota. Their study provides novel mechanistic evidence linking dietary cholesterol to pancreatic inflammation, addressing a critical gap left by earlier clinical observations that associated dietary cholesterol and dyslipidemia with pancreatic cancer risk but lacked mechanistic validation.
Read MoreGrowing recognition of the gut as a central regulator of health has increased scientific interest in probiotic-enriched foods, supported by microbiome research highlighting interactions between diet, gut microbes, and host physiology. Gut microbial dysbiosis is linked to gastrointestinal disorders and systemic conditions, making dietary strategies to restore microbial balance a key focus in preventive and therapeutic nutrition. Probiotic foods offer advantages for long-term use, although their efficacy is strain-specific and influenced by dose, food matrix, duration, and host factors. Selected probiotic strains can improve gastrointestinal function, bowel regularity, and intestinal barrier integrity through pathogen inhibition, bioactive metabolite production, and immune modulation.
Read MoreThis meta-analysis evaluated the efficacy of probiotics for vulvovaginal candidiasis and recurrent vulvovaginal candidiasis in non-pregnant women by analysing 14 randomized controlled trials identified from major databases up to October 12, 2025. Probiotics combined with antifungal therapy significantly improved short-term mycological and clinical cure rates and reduced 6-month recurrence, including improved 3-month combined cure in recurrent disease, although no sustained long-term benefits were observed and evidence certainty was low to very low. Probiotics used alone showed no short-term advantage over antifungal drugs and were inferior for long-term mycological cure, but demonstrated a significant benefit over placebo in improving 6-month mycological cure in recurrent vulvovaginal candidiasis. Overall, low-certainty evidence suggests probiotics may serve as a useful adjunct to antifungal therapy and a potential preventive or alternative option in selected cases, highlighting the need for high-quality trials to define optimal strains, regimens, and long-term outcomes.
Read MoreAdvances in sequencing have clarified the role of bacteria in tumor progression through their effects on the tumor microenvironment and immune regulation. Live bacterial therapy exploits the ability of bacteria, including probiotics, to selectively colonize tumors and activate antitumor immune responses, making it a promising cancer treatment strategy. Engineering approaches such as physicochemical modification and synthetic biology have improved the safety and efficacy of bacteria-based drug delivery systems. This review summarizes bacteria–tumor interactions, key engineering strategies, and their applications in cancer therapy, and highlights future opportunities including combination treatments, personalized medicine, and microbiome-guided approaches.
Read MoreAging is associated with low-grade intestinal inflammation, gut microbiota alterations, and impaired oxidative balance, and probiotic interventions to counter these changes remain underexplored in older adults. In this pilot trial, supplementation with Lactiplantibacillus plantarum OL3246 was well tolerated and led to consistent improvements across clinical, biochemical, and microbial outcomes, including reduced fecal calprotectin, improved oxidative stress markers, and enhanced gut microbiome diversity. Participants also reported better quality of life and mood. Overall, these findings suggest that L. plantarum OL3246 may beneficially modulate intestinal inflammation, oxidative status, and gut microbiota, supporting healthy aging.
Read MoreThis randomized, double-blind, placebo-controlled trial evaluated the effect of a multi-strain probiotic on common infections in children attending early childhood education settings over 24 weeks. In 118 enrolled children, probiotic supplementation (10 billion active units daily) resulted in a 62% reduction in gastrointestinal tract infections during the final 16 weeks, with a protective effect emerging after approximately 8 weeks, while no significant impact was observed on respiratory tract infections. Probiotic use was also associated with an estimated cost saving of AU$4748 related to reduced gastrointestinal infections. These findings suggest that multi-strain probiotics may lower gastrointestinal infection risk in childcare settings, although larger trials are needed to confirm efficacy and assess broader infectious outcomes.
Read More